{"id":12367,"date":"2026-05-28T16:00:00","date_gmt":"2026-05-28T14:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=c53973c1bd28165d0e828fa09e4b00fc"},"modified":"2026-05-28T16:00:00","modified_gmt":"2026-05-28T14:00:00","slug":"daiichi-sankyo-showcases-progress-across-industry-leading-oncology-portfolio-with-latest-research-updates-at-asco","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=12367","title":{"rendered":"Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\nNew analyses from five landmark trials of Enhertu\u00ae and Datroway\u00ae in breast and gastric cancer alongside pipeline data across other tumor types demonstrate continued oncology leadership<\/li>\n<li>\nEarly phase trials-in-progress featuring potential medicines with novel mechanisms highlight the company\u2019s commitment to identifying new breakthrough generating technologies for patients with cancer<\/li>\n<\/ul><p>TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26).<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260528097415\/en\/2326381\/5\/DS_logo_portrait_format_4color_rgb_120206.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260528097415\/en\/2326381\/22\/DS_logo_portrait_format_4color_rgb_120206.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260528097415\/en\/2326381\/5\/DS_logo_portrait_format_4color_rgb_120206.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260528097415\/en\/2326381\/21\/DS_logo_portrait_format_4color_rgb_120206.jpg\" \/><\/a><p>\nData at ASCO will highlight the company\u2019s progress toward advancing new standards of care for patients with cancer, including new analyses from five landmark trials in breast and gastric cancer, including the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04622319&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=DESTINY-Breast05&amp;index=1&amp;md5=7030a6f4d86b0c9353daa5a2800b3cb9\" rel=\"nofollow\" shape=\"rect\">DESTINY-Breast05<\/a> (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F263790&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=516&amp;index=2&amp;md5=c168ea51a6283bb3d2380ffd769d86ce\" rel=\"nofollow\" shape=\"rect\">516<\/a>), <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04494425&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=DESTINY-Breast06&amp;index=3&amp;md5=8bb5e80eb619177de0375a94a3964b22\" rel=\"nofollow\" shape=\"rect\">DESTINY-Breast06<\/a> (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F267396&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=1063&amp;index=4&amp;md5=54e4d89d98bc8412f809846eada647b0\" rel=\"nofollow\" shape=\"rect\">1063<\/a>), <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04784715&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=DESTINY-Breast09&amp;index=5&amp;md5=831f0f54cc0394bfcf6a941645997d04\" rel=\"nofollow\" shape=\"rect\">DESTINY-Breast09<\/a> (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F260858&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=1021&amp;index=6&amp;md5=23d96a64d715c72d485aec398e1a098f\" rel=\"nofollow\" shape=\"rect\">1021<\/a>) and <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04704934&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=DESTINY-Gastric04&amp;index=7&amp;md5=c082461a7c5b8c37cbac49f3b9bc7b0e\" rel=\"nofollow\" shape=\"rect\">DESTINY-Gastric04<\/a> (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F264005&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=4111&amp;index=8&amp;md5=6d269606819123fc85e500e8bfda287c\" rel=\"nofollow\" shape=\"rect\">4111<\/a>) phase 3 trials of Enhertu<sup>\u00ae<\/sup> (trastuzumab deruxtecan), and the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05374512&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TROPION-Breast02&amp;index=9&amp;md5=57adc63bd1faa9e116a79a8a2a6b3a6d\" rel=\"nofollow\" shape=\"rect\">TROPION-Breast02<\/a> (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F259333&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=1002&amp;index=10&amp;md5=b53a17d5535cb283192b80654a78cb7f\" rel=\"nofollow\" shape=\"rect\">1002<\/a>) phase 3 trial of Datroway<sup>\u00ae<\/sup> (datopotamab deruxtecan). Additional results from earlier phase trials as well as trials-in-progress across new medicines being developed through the company\u2019s breakthrough generating technology (BGT), a platform-based drug discovery model designed to deliver innovative medicines to patients faster, will be highlighted.<\/p><p>\nData from<b> <\/b><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04622319&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=DESTINY-Breast05&amp;index=11&amp;md5=27e6a628cf8082d19110b17bcaa84829\" rel=\"nofollow\" shape=\"rect\">DESTINY-Breast05<\/a> formed the basis of one of two new Enhertu indications recently <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdaiichisankyo.us%2Fpress-releases%2F-%2Farticle%2Fenhertu-approved-in%2525C2%2525A0the-us-for-two-new-indications-for-patients-with-her2-positive-early-breast-cancer-1&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=approved&amp;index=12&amp;md5=a7a2ea3aef7bad2d555a4d313a2bbd5d\" rel=\"nofollow\" shape=\"rect\">approved<\/a> in the U.S. for certain patients with early-stage HER2 positive breast cancer and data from <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04704934&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=DESTINY-Gastric04&amp;index=13&amp;md5=b20f2995f327009f57a9a374a2febc88\" rel=\"nofollow\" shape=\"rect\">DESTINY-Gastric04<\/a> was included as part of a label update to expand the use of Enhertu in <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.daiichisankyo.com%2Ffiles%2Fnews%2Fpressrelease%2Fpdf%2F202603%2F20260323_E3.pdf&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=Japan&amp;index=14&amp;md5=d2d19af3546fd28103a7cee0750bdb16\" rel=\"nofollow\" shape=\"rect\">Japan<\/a> and <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.daiichisankyo.com%2Ffiles%2Fnews%2Fpressrelease%2Fpdf%2F202601%2F20260122_E2.pdf&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=China&amp;index=15&amp;md5=2b9e5c4b80f3e077839a0813902a5b22\" rel=\"nofollow\" shape=\"rect\">China<\/a> to include the second-line treatment of patients with HER2 positive metastatic gastric cancer. Additionally, results from <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05374512&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TROPION-Breast02&amp;index=16&amp;md5=9aa55c06820a668c40a9266a77eaa562\" rel=\"nofollow\" shape=\"rect\">TROPION-Breast02<\/a> formed the basis of the recent <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdaiichisankyo.us%2Fpress-releases%2F-%2Farticle%2Fdatroway-approved-in-the-us-as-first-trop2-directed-antibody-drug-conjugate-for-first-line-treatment-of-patients-with-metastatic-triple-negative-breast-cancer-who-are-not-pd-1pd-l1-inhibitor-candidates&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=U.S.+approval&amp;index=17&amp;md5=0d8a3235f65212398413ae16605456c6\" rel=\"nofollow\" shape=\"rect\">U.S. approval<\/a> of Datroway in patients with metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1\/PD-L1 inhibitor therapy, the first antibody drug conjugate (ADC) to be approved in this setting of TNBC.<\/p><p>\n\u201cThe approvals received just prior to ASCO for Enhertu and Datroway, two of our leading DXd antibody drug conjugates, together with the strong science being showcased across our pipeline, highlight the momentum of our oncology portfolio,\u201d said John Tsai, MD, Global Head, R&amp;D, Daiichi Sankyo. \u201cDaiichi Sankyo is committed to creating new standards of care for patients with cancer and continues to leverage its scientific and technological expertise to advance innovation.\u201d<\/p><p>\n<b>Additional Enhertu Data Spans Broad Range of HER2 Expressing Cancers\n<br\/><\/b>Additional research updates across several additional HER2 expressing cancers include oral and poster sessions highlighting the preliminary safety run-in results from the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06819007&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=DESTINY-Ovarian01&amp;index=18&amp;md5=761bf331dc9ad33ad8129ff948323439\" rel=\"nofollow\" shape=\"rect\">DESTINY-Ovarian01<\/a> (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F261781&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=5554&amp;index=19&amp;md5=e2163a5c3d60084e3a771607c1179dd7\" rel=\"nofollow\" shape=\"rect\">5554<\/a>) phase 3 trial evaluating Enhertu in combination with bevacizumab compared to bevacizumab monotherapy as a first-line maintenance therapy in patients with HER2 expressing ovarian cancer; the primary analysis from part 1 of the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06271837&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=DESTINY-PanTumor03&amp;index=20&amp;md5=499c379dc38b0d9b115a14c1d2431653\" rel=\"nofollow\" shape=\"rect\">DESTINY-PanTumor03<\/a> (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F268182&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=3026&amp;index=21&amp;md5=0bec7f7ab0e6d759467f6e2febc04226\" rel=\"nofollow\" shape=\"rect\">3026<\/a>) phase 2 trial evaluating Enhertu in pretreated patients in China with HER2 positive (IHC 3+) solid tumors (excluding breast and gastric cancer); and, findings from the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fjrct.mhlw.go.jp%2Fen-latest-detail%2FjRCT2011210017&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=MYTHOS&amp;index=22&amp;md5=ded42f5616b5ac13c5a34f4ece191fe1\" rel=\"nofollow\" shape=\"rect\">MYTHOS<\/a> (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F260505&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=6011&amp;index=23&amp;md5=b92a9c31350fccdc8b7ac82499d59eac\" rel=\"nofollow\" shape=\"rect\">6011<\/a>) phase 2 trial evaluating Enhertu in patients with HER2-low recurrent or metastatic salivary gland cancer.<\/p><p>\nAdditional breast and gastric cancer data for Enhertu include an oral presentation from one arm of the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04538742&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=DESTINY-Breast07&amp;index=24&amp;md5=af837c6deee3dedf723a26fef070f853\" rel=\"nofollow\" shape=\"rect\">DESTINY-Breast07<\/a> (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F265398&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=1012&amp;index=25&amp;md5=16ff8727130acd59675fbd5a069e511f\" rel=\"nofollow\" shape=\"rect\">1012<\/a>) phase 1b\/2 trial evaluating Enhertu in combination with durvalumab as a first-line treatment in patients with HER2 positive metastatic breast cancer and a poster presentation highlighting a safety analysis from the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04379596&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=DESTINY-Gastric03&amp;index=26&amp;md5=d81f8e4c083f958a2a34fd7beab35f3e\" rel=\"nofollow\" shape=\"rect\">DESTINY-Gastric03<\/a> (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F263990&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=4022&amp;index=27&amp;md5=19bf7c6336d5943782966502475f5e2a\" rel=\"nofollow\" shape=\"rect\">4022<\/a>) phase 1b\/2 trial evaluating Enhertu in combination with chemotherapy and immunotherapy as a first-line treatment in patients with HER2 expressing metastatic gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma or esophageal adenocarcinoma.<\/p><p>\nResults from cohort two of the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fjrct.mhlw.go.jp%2Fen-latest-detail%2FjRCT2031230477&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=EPOC2203&amp;index=28&amp;md5=d7db677a9e182821157b3eafe21d62b0\" rel=\"nofollow\" shape=\"rect\">EPOC2203<\/a> (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F263995&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=4024&amp;index=29&amp;md5=a699d3e58c2d192fd79d0e5998db2578\" rel=\"nofollow\" shape=\"rect\">4024<\/a>) phase 1b\/2 trial evaluating Enhertu in combination with nivolumab and capecitabine and oxaliplatin in patients with HER2 low gastroesophageal adenocarcinoma and an exploratory analysis of translational data from the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05034887&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=EPOC2003&amp;index=30&amp;md5=9b005cf4b556915b798c5437c0184c13\" rel=\"nofollow\" shape=\"rect\">EPOC2003<\/a> (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F262187&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=3129&amp;index=31&amp;md5=eb8686d18552719fd317907e43992e06\" rel=\"nofollow\" shape=\"rect\">3129<\/a>) phase 2 trial evaluating neoadjuvant chemotherapy in combination with Enhertu in patients with HER2 positive gastric cancer will be highlighted as poster presentations.<\/p><p>\n<b>New Data and Trials-in-Progress Presentations Across Oncology Portfolio\n<br\/><\/b>Poster presentations will include a trial-in-progress update of <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06161025&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=REJOICE-Ovarian01&amp;index=32&amp;md5=990318f77a9aedf6ef50ab968e8c93f5\" rel=\"nofollow\" shape=\"rect\">REJOICE-Ovarian01<\/a> (<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F266944&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TPS5637&amp;index=33&amp;md5=4e7fe43933e7fb39b4ed560627a68f67\" rel=\"nofollow\" shape=\"rect\">TPS5637<\/a>) for the phase 3 part of a phase 2\/3 trial evaluating raludotatug deruxtecan (R-DXd) compared to treatment of physician\u2019s choice in patients with platinum-resistant ovarian cancer. Two additional poster presentations will highlight an exposure-response analysis (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F258093&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=5570&amp;index=34&amp;md5=e8f428a96fb1d46ed78d70320e0baf9a\" rel=\"nofollow\" shape=\"rect\">5570<\/a>) and a population pharmacokinetic analysis (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F258094&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=5571&amp;index=35&amp;md5=551413637870cf601ca9a74baa58fd12\" rel=\"nofollow\" shape=\"rect\">5571<\/a>) of data from both the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06161025&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=REJOICE-Ovarian01&amp;index=36&amp;md5=e6b223fb3933a6828f399a183521001b\" rel=\"nofollow\" shape=\"rect\">REJOICE-Ovarian01<\/a> phase 2\/3 trial and the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04707248&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=phase+1+trial&amp;index=37&amp;md5=a4388f07d01d32272fb3a28634c16b5f\" rel=\"nofollow\" shape=\"rect\">phase 1 trial<\/a> evaluating raludotatug deruxtecan in patients with advanced ovarian cancer or renal cell carcinoma.<\/p><p>\nAn oral presentation will highlight results from a <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03661307&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=phase+1%2F2+trial&amp;index=38&amp;md5=bd5db749b4d9b660d528527aa3ff3c67\" rel=\"nofollow\" shape=\"rect\">phase 1\/2 trial<\/a> (#<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F258982&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=6504&amp;index=39&amp;md5=8dadfd9723e3351cdc840a9b2a43685f\" rel=\"nofollow\" shape=\"rect\">6504<\/a>) of Vanflyta\u00ae (quizartinib) plus decitabine and venetoclax in patients with newly diagnosed or relapsed\/refractory <i>FLT3<\/i>-ITD acute myeloid leukemia.<\/p><p>\nTrials-in-progress poster presentations across the DXd ADC portfolio include the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07129993&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TROPION-Urothelial03&amp;index=40&amp;md5=36eae42e7e8ae491fcb53866496751a9\" rel=\"nofollow\" shape=\"rect\">TROPION-Urothelial03<\/a> (<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F266904&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TPS4642&amp;index=41&amp;md5=2df7e7258265654d7d56ae397535bffe\" rel=\"nofollow\" shape=\"rect\">TPS4642<\/a>) phase 2\/3 trial evaluating Datroway and platinum chemotherapy compared to gemcitabine plus platinum chemotherapy in patients with locally advanced or metastatic urothelial carcinoma; the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07060807&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=HERTHENA-Breast04&amp;index=42&amp;md5=7c4bf05f46b858e179983449a6edb621\" rel=\"nofollow\" shape=\"rect\">HERTHENA-Breast04<\/a> (<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F266612&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TPS1149&amp;index=43&amp;md5=b77ef33e5c5034b568663ed61c024774\" rel=\"nofollow\" shape=\"rect\">TPS1149<\/a>) phase 3 trial evaluating patritumab deruxtecan (HER3-DXd) compared to treatment of physician\u2019s choice in patients with HR positive, HER2 negative unresectable locally advanced or metastatic breast cancer; and the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07124000&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=DESTINY-PanTumor04&amp;index=44&amp;md5=bb0c956ddf5fcf4d8ec10a094d78acb9\" rel=\"nofollow\" shape=\"rect\">DESTINY-PanTumor04<\/a> (<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F266975&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TPS11202&amp;index=45&amp;md5=db00a3b19a17a83777e45c188febd073\" rel=\"nofollow\" shape=\"rect\">TPS11202<\/a>) hybrid observational trial evaluating Enhertu in patients with HER2 positive (IHC 3+) solid tumors.<\/p><p>\n<b>Trials-in-Progress Presentations Highlight Breakthrough Generating Technology Focus\n<br\/><\/b>Daiichi Sankyo is leveraging its strength in science and technology to create new medicines for patients with cancer through its BGT approach which is designed to deliver innovative medicines to patients faster and with a higher probability of success. Trials-in-progress poster presentations featuring three potential new medicines include <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07159126&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=DS3610&amp;index=46&amp;md5=f8a99776b69bd537767ffe8610985e3b\" rel=\"nofollow\" shape=\"rect\">DS3610<\/a> (<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F266825&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TPS3159&amp;index=47&amp;md5=3458d9eed87b437fa2b83e534cb13e64\" rel=\"nofollow\" shape=\"rect\">TPS3159<\/a>), a STING (stimulator of interferon genes) ADC, in patients with advanced or metastatic solid tumors; <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07182591&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=DS5361&amp;index=48&amp;md5=ca477337a9b86ddf8c9b6550394a6479\" rel=\"nofollow\" shape=\"rect\">DS5361<\/a> (<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F266787&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TPS2680&amp;index=49&amp;md5=718d5d1d4e65fb15c386489c80c1252a\" rel=\"nofollow\" shape=\"rect\">TPS2680<\/a>), a small-molecule, nonsense-mediated mRNA decay inhibitor, in patients with advanced or metastatic solid tumors; and, <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07189403&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=DS9051&amp;index=50&amp;md5=eda92c35c8b7679bd8d538d05bcedda8\" rel=\"nofollow\" shape=\"rect\">DS9051<\/a> (<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F266826&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TPS3179&amp;index=51&amp;md5=174360249730da7d5cb8ae872784b6a1\" rel=\"nofollow\" shape=\"rect\">TPS3179<\/a>), a novel targeted protein degradation molecule, in patients with advanced or metastatic adrenocortical carcinoma or metastatic castration-resistant prostate cancer.<\/p><p>\nOverview of clinical data and trials-in-progress from oncology pipeline of Daiichi Sankyo include:<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl0\" colspan=\"2\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Presentation Title<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Author<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignl bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<b>Abstract<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Presentation (CDT)<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth10\" colspan=\"1\" rowspan=\"8\"><p class=\"bwalignc bwcellpmargin\">\n<b>Breast<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nA DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nY. Park<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F260858&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=1021&amp;index=52&amp;md5=7dec4b213e7a68772524fd7b4069b379\" rel=\"nofollow\" shape=\"rect\">1021<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nRapid Oral Presentation\n<br\/>Sunday, May 31\n<br\/>11:30 am \u2013 1:00 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nSecondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: clinical and demographic risk factors of interstitial lung disease and radiation pneumonitis<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nM. Untch<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F263790&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=516&amp;index=53&amp;md5=b7c22d2a3c2aa33405346013ff403960\" rel=\"nofollow\" shape=\"rect\">516<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nRapid Oral Presentation\n<br\/>Monday, June 1\n<br\/>9:45 \u2013 11:15 am<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nNeoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nC. O\u2019Sullivan<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignl bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F258687&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=LBA514&amp;index=54&amp;md5=2ef9deb78518de2ba61eecaf912f5b24\" rel=\"nofollow\" shape=\"rect\">LBA514<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nRapid Oral Presentation\n<br\/>Monday, June 1\n<br\/>9:45 \u2013 11:15 am<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTrastuzumab deruxtecan (T-DXd) + durvalumab in patients with previously untreated HER2 positive unresectable\/metastatic breast cancer (mBC): final analysis from DESTINY-Breast07<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nS. Loi<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F265398&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=1012&amp;index=55&amp;md5=fc6e86065ffc30fd336ba83b2b19de16\" rel=\"nofollow\" shape=\"rect\">1012<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nOral Presentation\n<br\/>Sunday, May 31\n<br\/>8:30 \u2013 10:00 am<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nFirst-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple negative breast cancer for whom immunotherapy was not an option: additional efficacy endpoints from the TROPION-Breast02 study<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nD. Cescon<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F259333&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=1002&amp;index=56&amp;md5=b841e08c98211a2dd8d99ecbd56ccbcc\" rel=\"nofollow\" shape=\"rect\">1002<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nOral Presentation\n<br\/>Tuesday, June 2\n<br\/>9:45 am \u2013 12:45 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nImpact of adherence to interstitial lung disease (ILD)\/pneumonitis toxicity management guidelines on ILD\/pneumonitis outcomes: a retrospective analysis of patients treated with trastuzumab deruxtecan (T-DXd) in DESTINY-Breast06<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nC. Mateo<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F267396&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=1063&amp;index=57&amp;md5=49c902ac2d7310ce97c1fac7d0b06010\" rel=\"nofollow\" shape=\"rect\">1063<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Monday, June 1\n<br\/>1:30 \u2013 4:30 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nHERTHENA-Breast04: a phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician\u2019s choice in hormone receptor positive (HR +)\/HER2-) unresectable locally advanced or metastatic breast cancer<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nB. Pistilli<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignl bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F266612&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TPS1149&amp;index=58&amp;md5=0521460dbaccd4a38b00a741e25ffed3\" rel=\"nofollow\" shape=\"rect\">TPS1149<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Monday, June 1\n<br\/>1:30 \u2013 4:30 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nIdentifying patients with human epidermal growth factor receptor 2 (HER2) low and ultralow breast cancer: use of digital, artificial intelligence-based computational algorithms to assist HER2 scoring by pathologists<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nS. Krishnamurthy<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F261196&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=1022&amp;index=59&amp;md5=7a6d8ab3f1a4bb32c9cd5e6ec81d385b\" rel=\"nofollow\" shape=\"rect\">1022<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Monday, June 1\n<br\/>1:30 \u2013 4:30 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth10\" colspan=\"1\" rowspan=\"4\"><p class=\"bwalignc bwcellpmargin\">\n<b>Gastric<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nAdditional health-related quality of life analysis from DESTINY-Gastric04, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs ramucirumab + paclitaxel in patients with HER2 positive unresectable\/metastatic gastric cancer\/gastroesophageal junction adenocarcinoma<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nK. Shitara<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F264005&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=4111&amp;index=60&amp;md5=2b30490f6fbed0e7a4de2d758bb91271\" rel=\"nofollow\" shape=\"rect\">4111<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Saturday, May 30\n<br\/>9:00 am \u2013 12:00 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nFirst-line trastuzumab deruxtecan (T-DXd)-based regimens in advanced HER2 expressing gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: safety results from DESTINY-Gastric03 Part 2 arms D and F, and Part 4<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nY. Janjigian<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F263990&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=4022&amp;index=61&amp;md5=73836cb6b1597e330ef6758a6545fc2c\" rel=\"nofollow\" shape=\"rect\">4022<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Saturday, May 30\n<br\/>9:00 am \u2013 12:00 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nAn open-label phase 1b\/2 study of trastuzumab deruxtecan combined with nivolumab and CAPOX in patients with HER2 low gastroesophageal adenocarcinoma (EPOC2203)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nY. Aoki<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F263995&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=4024&amp;index=62&amp;md5=545669bd2654f88a9ebe709bbe5d818f\" rel=\"nofollow\" shape=\"rect\">4024<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Saturday, May 30\n<br\/>9:00 am \u2013 12:00 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTumor and immune microenvironment remodeling with neoadjuvant trastuzumab deruxtecan in HER2 positive gastric cancer: exploratory analyses from the phase 2 EPOC2003 study<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nA. Kawazoe<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F262187&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=3129&amp;index=63&amp;md5=615dfb9d88ab687c59a3965c02a659fd\" rel=\"nofollow\" shape=\"rect\">3129<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Saturday, May 30\n<br\/>1:30 \u2013 4:30 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth10\" colspan=\"1\" rowspan=\"4\"><p class=\"bwalignc bwcellpmargin\">\n<b>Ovarian<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTrastuzumab deruxtecan (T-DXd) + bevacizumab (BEV) as first-line (1L) maintenance therapy in patients with HER2 expressing ovarian cancer: results from the DESTINY-Ovarian01 safety run-in<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nA. Gonzalez Martin<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F261781&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=5554&amp;index=64&amp;md5=8b1e31be1fd801aa5a3db2072b65b243\" rel=\"nofollow\" shape=\"rect\">5554<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Monday, June 1\n<br\/>9:00 am \u2013 12:00 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nREJOICE-Ovarian01: phase 3 part of a phase 2\/3 study evaluating raludotatug deruxtecan (R-DXd) versus treatment of physician\u2019s choice in patients with platinum-resistant ovarian cancer<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nD. Richardson<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignl bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F266944&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TPS5637&amp;index=65&amp;md5=b84695a943a798253db47de723f10a40\" rel=\"nofollow\" shape=\"rect\">TPS5637<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Monday, June 1\n<br\/>9:00 am \u2013 12:00 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nExposure-response analyses of efficacy and safety with raludotatug deruxtecan (R-DXd), a CDH6-directed ADC, to inform dose selection for phase 3 development in platinum-resistant ovarian cancer<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nF. Hurtado<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F258093&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=5570&amp;index=66&amp;md5=79f7c63ac0866ebfc2bce1890edbf2e4\" rel=\"nofollow\" shape=\"rect\">5570<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Monday, June 1\n<br\/>9:00 am \u2013 12:00 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPopulation pharmacokinetic analysis of raludotatug deruxtecan (R-DXd), a CDH6-directed ADC, in patients with advanced ovarian cancer or renal cell carcinoma<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nF. Hurtado<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F258094&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=5571&amp;index=67&amp;md5=076ba1f0285a55bffb23a92cb6d8581a\" rel=\"nofollow\" shape=\"rect\">5571<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Monday, June 1\n<br\/>9:00 am \u2013 12:00 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>Urothelial<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTROPION-Urothelial03: a phase 2\/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy vs gemcitabine + platinum chemotherapy in participants with locally advanced or metastatic urothelial carcinoma with progression on or after enfortumab vedotin + pembrolizumab<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nM. Galsky<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignl bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F266904&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TPS4642&amp;index=68&amp;md5=51cccdf27eb4a49a04c466112006d481\" rel=\"nofollow\" shape=\"rect\">TPS4642<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Sunday, May 31\n<br\/>9:00 am \u2013 12:00 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>Salivary<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTrastuzumab deruxtecan in patients with HER2 low recurrent\/metastatic salivary gland carcinoma: results from the phase 2 MYTHOS trial<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nI. Kinoshita<\/p><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F260505&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=6011&amp;index=69&amp;md5=d5d29de971ace195c9f10151805ba89b\" rel=\"nofollow\" shape=\"rect\">6011<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nOral Presentation\n<br\/>Monday, June 1\n<br\/>8:00 \u2013 9:30 am<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>AML<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nQuizartinib in combination with decitabine and venetoclax for newly diagnosed and relapsed\/refractory <i>FLT3 <\/i>mutated acute myeloid leukemia<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nM. Yilmaz<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F258982&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=6504&amp;index=70&amp;md5=e7601fb3d321483480c72f43d645e88f\" rel=\"nofollow\" shape=\"rect\">6504<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nOral Presentation\n<br\/>Tuesday, June 2\n<br\/>9:45 am \u2013 12:45 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth10\" colspan=\"1\" rowspan=\"4\"><p class=\"bwalignc bwcellpmargin\">\n<b>Pan Tumor<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTrastuzumab deruxtecan (T-DXd) for pretreated patients in China with HER2 IHC 3+ solid tumors: DESTINY-PanTumor03 Part 1 primary analysis<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nY. Zhang<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F268182&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=3026&amp;index=71&amp;md5=39b0454cb63dbca8c89db690e5b224ad\" rel=\"nofollow\" shape=\"rect\">3026<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Saturday, May 30\n<br\/>1:30 \u2013 4:30 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nA pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with HER2 IHC3+ solid tumors: DESTINY-PanTumor04<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nB. Monk<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignl bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F266975&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TPS11202&amp;index=72&amp;md5=f16c7c761c7024e8203994a3ba9e9d79\" rel=\"nofollow\" shape=\"rect\">TPS11202<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Monday, June 1\n<br\/>9:00 am \u2013 12:00 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nHER2 independent antitumor and pharmacodynamic responses to trastuzumab deruxtecan in patients with advanced solid tumors<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nS. Shin<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F263247&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=3031&amp;index=73&amp;md5=2414bb65a44e6b53200ead05bd4f5b15\" rel=\"nofollow\" shape=\"rect\">3031<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Saturday, May 30\n<br\/>1:30 \u2013 4:30 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTopoisomerase 1 and DNA damage: pharmacodynamic responses and mechanism of trastuzumab deruxtecan in HER2-expressing advanced solid tumors<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nD. Wilsker<\/p><\/td><td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F261762&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=3092&amp;index=74&amp;md5=9b19568925bbd4d6175b284ea5857f9f\" rel=\"nofollow\" shape=\"rect\">3092<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Saturday, May 30\n<br\/>1:30 \u2013 4:30 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth10\" colspan=\"1\" rowspan=\"3\"><p class=\"bwalignc bwcellpmargin\">\n<b>BGT<\/b><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nA phase 1, first-in-human study of DS3610, a stimulator of interferon genes (STING) agonist ADC, in patients with advanced\/metastatic solid tumors<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nS. Koganemaru<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignl bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F266825&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TPS3159&amp;index=75&amp;md5=b12a187f0b052ad21ee9008b8e4de429\" rel=\"nofollow\" shape=\"rect\">TPS3159<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Saturday, May 30\n<br\/>1:30 \u2013 4:30 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nA phase 1, first-in-human study of DS5361, a small-molecule, nonsense-mediated mRNA decay inhibitor, in patients with advanced\/metastatic solid tumors (Parts 1 and 2)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nS. Sen<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignl bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F266787&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TPS2680&amp;index=76&amp;md5=c95b1ddfe2a9cddbe89fae5a386b0d33\" rel=\"nofollow\" shape=\"rect\">TPS2680<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Saturday, May 30\n<br\/>1:30 \u2013 4:30 pm<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth45\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nA phase 1, first-in-human study of DS9051, a novel targeted protein degradation molecule, in patients with advanced\/metastatic adrenocortical carcinoma or metastatic castration-resistant prostate cancer<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nM. Patel<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignl bwwidth10\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignl\">\n<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2F266826&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=TPS3179&amp;index=77&amp;md5=d3e13cb71f4d33d2048437b51038ecd0\" rel=\"nofollow\" shape=\"rect\">TPS3179<\/a><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth20\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPoster Session\n<br\/>Saturday, May 30\n<br\/>1:30 \u2013 4:30 pm<\/p><\/td><\/tr>\n<\/table><p>\n<b>About the ADC Portfolio of Daiichi Sankyo\n<br\/><\/b>The Daiichi Sankyo ADC portfolio consists of eight ADCs in clinical development crafted from ADC technology discovered in-house by Daiichi Sankyo.<\/p><p>\nThe DXd ADC Technology platform of Daiichi Sankyo consists of seven ADCs in clinical development where each ADC is comprised of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADCs include Enhertu and Datroway, which are being jointly developed and commercialized globally with AstraZeneca, and ifinatamab deruxtecan (I-DXd), raludotatug deruxtecan (R-DXd) and patritumab deruxtecan (HER3-DXd), which are being jointly developed and commercialized globally with Merck &amp; Co., Inc, Rahway, NJ, USA. DS-3939 and DS3790 are being developed by Daiichi Sankyo.<\/p><p>\nAn additional ADC being developed by Daiichi Sankyo is DS3610, which consists of an antibody attached to a novel payload that acts as an agonist of STING.<\/p><p>\nIfinatamab deruxtecan, raludotatug deruxtecan, patritumab deruxtecan, DS-3939, DS3610 and DS3790 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established.<\/p><p>\n<b>About Daiichi Sankyo\n<br\/><\/b>Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.daiichisankyo.com%2F&amp;esheet=54542808&amp;newsitemid=20260528097415&amp;lan=en-US&amp;anchor=www.daiichisankyo.com&amp;index=78&amp;md5=73b48b5645c71e530bd73a430e5ad9fc\" rel=\"nofollow\" shape=\"rect\">www.daiichisankyo.com<\/a>.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>MEDIA CONTACTS:<\/b><br\/><b>Global:<\/b><br\/>Jennifer Brennan\n<br\/><a  href=\"mailto:jennifer.brennan@daiichisankyo.com\" rel=\"nofollow\" shape=\"rect\"><b><i>jennifer.brennan@daiichisankyo.com<\/i><\/b><\/a><br\/>+1 908 900 3183 (mobile)<\/p><p>\n<b>Japan:<\/b><br\/><a  href=\"mailto:DS-PR_jp@daiichisankyo.com\" rel=\"nofollow\" shape=\"rect\"><b><i>DS-PR_jp@daiichisankyo.com<\/i><\/b><\/a><\/p><p>\n<b>INVESTOR RELATIONS CONTACT:<\/b><br\/><a  href=\"mailto:DaiichiSankyoIR_jp@daiichisankyo.com\" rel=\"nofollow\" shape=\"rect\"><b><i>DaiichiSankyoIR_jp@daiichisankyo.com<\/i><\/b><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>New analyses from five landmark trials of Enhertu\u00ae and Datroway\u00ae in breast and gastric cancer alongside pipeline data across other tumor types demonstrate continued oncology leadership<\/p>\n<p>Early phase trials-in-progress featuring potential medicines wit&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-12367","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12367"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12367\/revisions"}],"predecessor-version":[{"id":12368,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12367\/revisions\/12368"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}